Fiona C. Burkhard

Fiona C. Burkhard

Auto-generated profile, based on publicly available information

Fiona C. Burkhard

Department of Urology, Inselspital, Bern University Hospital, University of Bern

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AGAli Hashemi Gheinani
Ali Hashemi Gheinani
MVMike Vögeli
Mike Vögeli
UBUlrich Baumgartner
Ulrich Baumgartner
EVErik Vassella
Erik Vassella
ADAnnette Draeger
Annette Draeger
KMKatia Monastyrskaya
Katia Monastyrskaya
Circulating miRNAs are detected in extracellular space and body fluids such as urine. Circulating RNAs can be packaged in secreted urinary extracellular vesicles (uEVs) and thus protected from degradation. Urinary exosome preparations might contain specific miRNAs, relevant as biomarkers in renal and bladder diseases. Major difficulties in application of uEVs into the clinical environment are the high variability and low reproducibility of uEV isolation methods. Here we used five different methods to isolate uEVs and compared the size distribution, morphology, yield, presence of exosomal protein markers and RNA content of uEVs. We present an optimized ultracentrifugation and size exclusion chromatography approach for highly reproducible isolation for 50–150 nm uEVs, corresponding to the exosomes, from 50 ml urine. We profiled the miRNA content of uEVs and total urine from the same samples with the NanoString platform and validated the data using qPCR. Our results indicate that 18 miRNAs, robustly detected in uEVs were always present in the total urine. However, 15 miRNAs could be detected only in the total urine preparations and might represent naked circulating miRNA species. This is a novel unbiased and reproducible strategy for uEVs isolation, content normalization and miRNA cargo analysis, suitable for biomarker discovery studies.

3 March 2005 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
TKThomas M. Kessler
Thomas M. Kessler
HDHansjörg Danuser
Hansjörg Danuser
MSMartin Schumacher
Martin Schumacher
USUrs E. Studer
Urs E. Studer
FBFiona C. Burkhard
Fiona C. Burkhard

1 May 2014 in Journal of Urology
Verified
Journal Article
Closed access
RSRoland Seiler
Roland Seiler
USUrs E. Studer
Urs E. Studer
KTKonrad Tschan
Konrad Tschan
PBPia Bader
Pia Bader
FBFiona C. Burkhard
Fiona C. Burkhard
In 2003 we reported on the outcomes of 88 patients with node positive disease who underwent radical prostatectomy and pelvic lymph node dissection (median 21 nodes) between 1989 and 1999. Patients with limited nodal disease appeared to have a good chance of long-term survival, even without immediate adjuvant therapy (androgen deprivation therapy and/or radiotherapy). In this study we update the followup in these patients and verify the reported projected probability of survival. The projected 10-year cancer specific survival probability after the initially reported followup of 3.2 years was 60% for these patients with node positive disease. The outcome has been updated after a median followup of 15.6 years. Of the 39 patients with 1 positive node 7 (18%) remained biochemically relapse-free, 11 (28%) showed biochemical relapse only and 21 (54%) experienced clinical progression. Of these 39 patients 22 (57%) never required deferred androgen deprivation therapy and 12 (31%) died of prostate cancer. All patients with 2 (20) or more than 2 (29) positive nodes experienced biochemical relapse and only 5 (10%) of these 49 experienced no clinical progression. Of these 49 patients 39 (80%) received deferred androgen deprivation therapy. Biochemical relapse is likely in patients with limited nodal disease after radical prostatectomy and pelvic lymph node dissection, but for 46% of patients this does not imply death from prostate cancer. Patients with 1 positive node have a good (75%) 10-year cancer specific survival probability and a 20% chance of remaining biochemical relapse-free even without immediate adjuvant therapy.

1 August 2014 in European Urology
Verified
Journal Article
Closed access
PWPatrick Y. Wuethrich
Patrick Y. Wuethrich
USUrs E. Studer
Urs E. Studer
GTGeorge N. Thalmann
George N. Thalmann
FBFiona C. Burkhard
Fiona C. Burkhard

1 August 2002 in European Urology
Verified
Journal Article
Closed access
FBFiona C Burkhard
Fiona C Burkhard
PBPia Bader
Pia Bader
ESEric Schneider
Eric Schneider
RMRegula Markwalder
Regula Markwalder
USUrs E Studer
Urs E Studer

26 January 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
AGAli Hashemi Gheinani
Ali Hashemi Gheinani
BKBernhard Kiss
Bernhard Kiss
FMFelix Moltzahn
Felix Moltzahn
IKIrene Keller
Irene Keller
RBRémy Bruggmann
Rémy Bruggmann
KMKatia Monastyrskaya
Katia Monastyrskaya
Bladder outlet obstruction (BOO) induces significant organ remodeling, leading to lower urinary tract symptoms accompanied by urodynamic changes in bladder function. Here, we report mRNA and miRNA transcriptome sequencing of bladder samples from human patients with different urodynamically defined states of BOO. Patients’ miRNA and mRNA expression profiles correlated with urodynamic findings. Validation of RNA sequencing results in an independent patient cohort identified combinations of 3 mRNAs (NRXN3, BMP7, UPK1A) and 3 miRNAs (miR-103a-3p, miR-10a-5p, miR-199a-3p) sufficient to discriminate between bladder functional states. All BOO patients shared cytokine and immune response pathways, TGF-β and NO signaling pathways, and hypertrophic PI3K/AKT signaling pathways. AP-1 and NFkB were dominant transcription factors, and TNF-α was the top upstream regulator. Integrated miRNA-mRNA expression analysis identified pathways and molecules targeted by differentially expressed miRNAs. Molecular changes in BOO suggest an increasing involvement of miRNAs in the control of bladder function from the overactive to underactive/acontractile states.